A Phase 1 Study of RO7623066 Alone and in Combination in Patients with Advanced Solid Tumors
NCT #
NCT05240898
Condition(s)
Ovarian/ Peritoneal/ Fallopian Tube Cancer, Solid Tumor
Molecular Target(s)
USP1
Drug Classification(s)
Molecular Targeted Therapy, Small Molecule
Agents(s)
RO7623066
Phase(s)
I
Mechanism of Action
Small molecule inhibitor of USP1
Purpose
In this study, the sponsor and investigators want to learn:
- How much of RO7623066 can be given with an acceptable level of side effects alone and in combination with an oral PARP inhibitor or platinum-based chemotherapy
- The effects of RO7623066 (good and bad) alone and in combination with an oral PARP inhibitor or platinum-based chemotherapy
- How much of RO7623066 is absorbed into the blood and how fast it is removed
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.